DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for dermatitis herpetiformis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDermatitis herpetiformis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dermatitis herpetiformis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitogen-activated protein kinase 14 (MAPK14) — MAPK14 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bogdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3OEF · 1.6 Å · ligand octyl beta-D-glucopyranoside (BOG). Experimental structure, not a prediction.
What the evidence adds up to
The 1972 paper by Burrows reports a prevalence study of dermatitis herpetiformis in Northern Ireland but provides no numerical data in the abstract. A 2011 paper by Fry states that the incidence and prevalence of dermatitis herpetiformis are falling, again without specific figures in the abstract. A 2021 review describes the clinical features, pathomechanism, diagnostic algorithm, and the up-to-date management protocol based on the evidence- and consensus-based S2 guideline published by the European Academy of Dermatology. A 2002 paper by Leonard on management of dermatitis herpetiformis provides no numerical outcomes in its abstract.
A 1959 case series presented by Costello described five patients with dermatitis herpetiformis of 6 to 29 years duration who were treated with Diasone (a sulfone drug). Excellent control was achieved, and the patients were shown with practically no lesions. Discussant Traub noted that the doses tolerated were surprisingly high and that Diasone seemed far superior to other remedies available at that time. No response rates, survival data, or sample sizes beyond the five patients are given in the abstract.
The evidence for drug repurposing in dermatitis herpetiformis remains extremely thin. The 1959 Diasone series is a small, uncontrolled observation with no modern comparator. The more recent abstracts provide no drug-specific efficacy data. What is missing is any randomised controlled trial of a repurposed drug, adequate funding for such a trial, and a clear patient stratification strategy that might identify which patients could benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 1972 · 8 citations
The Prevalence of Dermatitis Herpetiformis
AbstractJournal Article The Prevalence of Dermatitis Herpetiformis Get access D. Burrows D. Burrows The Department of Dermatology royal Victoria Hospital Belfast BT12 6BA Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 86, Issue 4, 1 April 1972, Page 437, https://doi.org/10.1111/j.1365-2133.1972.tb05060.x Published: 01 April 1972
British Journal of Dermatology · 2011 · 6 citations
The falling incidence and prevalence of dermatitis herpetiformis
AbstractJournal Article The falling incidence and prevalence of dermatitis herpetiformis Get access L. Fry L. Fry Room G3, St Mary's Campus, Imperial College, London W2 1PG, U.K. E‐mail: [email protected] Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 2, 1 August 2011, Page 229, https://doi.org/10.1111/j.1365-2133.2011.10460.x Published: 01 August 2011
AbstractJOUMNA COMMENTTwelve cases of dermatitis herpetiformis were treated with sulphamethoxypyridazine; one of them was of a seyere bullous type and four were of the juvenile variety.Response in all these cases was most satisfactory.Several patients who had already received the usual controls for the disease declared spontaneously that the present treatment was the most pleasant and the most effective.One adult and three juvenile patients remained well after cessation of treat- ment.
Bőrgyógyászati és Venerológiai Szemle · 2021 · 0 citations · open access
The novel aspects of the diagnostics and therapy of dermatitis herpetiformis
AbstractIn the present review, the authors briefy describe the clinical features and pathomechanism of dermatitis herpetiformis and detail the diagnostic algorithm of the disease. The up-to-date protocol for the management of the disease is presented in light of the evidence- and consensus-based (S2) guideline published by the European Academy of Dermatology (EADV) in 2021.
Clinical and Experimental Dermatology · 2002 · 0 citations
Management of dermatitis herpetiformis
AbstractJournal Article Management of dermatitis herpetiformis Get access J. Leonard J. Leonard St Mary's Hospital, London, UK Search for other works by this author on: Oxford Academic Google Scholar Clinical and Experimental Dermatology, Volume 27, Issue 4, 1 June 2002, Pages 328–337, https://doi.org/10.1046/j.1365-2230.2002.104322.x Published: 01 June 2002
Abstract<b>Dermatitis Herpetiformis of Long Duration, Treated with Diasone</b>. Presented byDr. Maurice J. Costello. A group of five patients with dermatitis herpetiformis, showing severe involvement and with a duration of from 6 to 29 years, was shown. All had been treated with Diasone, and excellent control had been achieved. Discussion Dr. Eugene F. Traub: This is a very fine demonstration of dermatitis herpetiformis brought under control. Certainly in the older days it could not have been done. I was amazed at the size of the doses that have been tolerated by these patients. Perhaps the only way you can get a complete remission in these cases is to give a dose to the point of tolerance. It is unique to show five patients who have practically no lesions, especially those who have had the disease for a long time. Diasone certainly seems to be far superior to the other remedies
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
